Clinical Scorecard: FDA Clears Avulux Migraine Lenses
At a Glance
Category
Detail
Condition
Migraine-associated light sensitivity
Key Mechanisms
Precision light-filtering lenses designed to block specific wavelengths of light (480 nm and 590 nm) while allowing the rest of the visible spectrum to pass through.
Target Population
Patients aged 12 years and older with episodic migraine
Care Setting
Eye care providers and optical practices
Key Highlights
FDA granted De Novo marketing authorization for Avulux lenses.
Lenses block light at 480 nm and 590 nm, targeting light sensitivity.
Up to 90% of migraine patients experience light sensitivity.
Lenses are available over-the-counter and can be prescribed.
More than 50,000 users have been dispensed the lenses.
Guideline-Based Recommendations
Diagnosis
Patients should be diagnosed with episodic migraine and clinically significant light sensitivity.
Management
Patients are advised to continue standard migraine treatments alongside the use of Avulux lenses.
Monitoring & Follow-up
Monitor the effectiveness of the lenses in reducing light sensitivity and migraine attacks.
Risks
Potential for light sensitivity to trigger migraine attacks remains.
Patient & Prescribing Data
Adolescents and adults with episodic migraine experiencing light sensitivity.
Lenses are intended to complement existing migraine treatments, not replace them.
Clinical Best Practices
Educate patients on the use of Avulux lenses in conjunction with prescribed migraine medications.
Assess the impact of light sensitivity on patients' migraine frequency and severity.
Pediatric migraine has historically been managed in fragments – symptoms recalled across months of episodic appointments. At Phoenix Children's, digital tools are reshaping care from episodic to continuous.
